Early effect of tacrolimus in improving excitation-contraction coupling in myasthenia gravis

Clinical Neurophysiology

Volumn 123, Issue 9, 2012, Pages 1886-1890

  Imai, Tomihiro ^a   Tsuda, Emiko ^a   Hozuki, Takayoshi ^a   Yamauchi, Rika ^a   Saitoh, Masaki ^a   Hisahara, Shin ^a   Yoshikawa, Hiroaki ^b   Motomura, Masakatsu ^c   Kawamata, Jun ^a   Shimohama, Shun ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c NAGASAKI UNIVERSITY   (Japan)

Author keywords

Bite force; Excitation contraction coupling; Masseter; Myasthenia gravis; Tacrolimus

Indexed keywords

ANTIBODY; CHOLINERGIC RECEPTOR ANTIBODY; PROTEIN TYROSINE KINASE ANTIBODY; RYANODINE RECEPTOR ANTIBODY; TACROLIMUS; UNCLASSIFIED DRUG;

ACTION POTENTIAL; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EXCITATION CONTRACTION COUPLING; FEMALE; HUMAN; LATENT PERIOD; MALE; MASSETER MUSCLE; MASTICATION; MOVEMENT RELATED POTENTIAL; MUSCLE ACTION POTENTIAL; MYASTHENIA GRAVIS; NERVE STIMULATION; PRIORITY JOURNAL; TRIGEMINAL NERVE STIMULATION;

ADULT; AGED; BITE FORCE; CASE-CONTROL STUDIES; ELECTRIC STIMULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EVOKED POTENTIALS, MOTOR; EXCITATION CONTRACTION COUPLING; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MASSETER MUSCLE; MIDDLE AGED; MUSCLE, SKELETAL; MYASTHENIA GRAVIS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CHOLINERGIC; RETROSPECTIVE STUDIES; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TIME FACTORS;

EID: 84864396211     PISSN: 13882457     EISSN: 18728952     Source Type: Journal    
DOI: 10.1016/j.clinph.2012.01.017     Document Type: Article

References (36)

1. Bhat M.B., Zhao J., Takeshima H., Ma J. Functional calcium release channel formed by the carboxyl-terminal portion of ryanodine receptor. Biophys J 1997, 73:1329-1336.
2. Brillantes A.B., Ondrias K., Scott A., Kobrinsky E., Ondriasova E., Moschella M.C., et al. Stabilization of calcium release channel (ryanodine receptor) function by FK506-binding protein. Cell 1994, 77:513-523.
3. Chelu M.G., Danila C.I., Gilman C.P., Hamilton S.L. Regulation of ryanodine receptors by FK506 binding proteins. Trends Cardiovasc Med 2004, 14:227-234.
4. Evoli A., Di Schino C., Marsili F., Punzi C. Successful treatment of myasthenia gravis with tacrolimus. Muscle Nerve 2002, 25:111-114.
5. Franzini-Armstrong C., Nunzi G. Junctional feet and particles in the triads of a fast-twitch muscle fibre. J Muscle Res Cell Motil 1983, 4:233-252.
6. Imai T, Tsuda E, Hozuki T, Hisahara S, Nonaka M, Shimohama S. Measurement of excitation-contraction coupling time of masseter in lower jaw movement. The XVIth International SFEMG and QEMG course and the IXth QEMG conference proceedings 2007:p. 187.
7. Imai T., Tsuda E., Hozuki T., Yoshikawa H., Yamauchi R., Saitoh M., et al. Contribution of anti-ryanodine receptor antibody to impairment of excitation-contraction coupling in myasthenia gravis. Clin Neurophysiol 2011, 10.1016/j.clinph.2011.10.038.
8. Jaretzki A., Barohn R.J., Ernstoff R.M., Kaminski H.J., Keesey J.C., Penn A.S., et al. Myasthenia gravis: recommendations for clinical research standards. Neurology 2000, 55:16-23.
9. Jayaraman T., Brillantes A.M., Timerman A.P., Fleischer S., Erdjument-Bromage H., Tempst P., et al. FK506 binding protein associated with the calcium release channel (ryanodine receptor). J Biol Chem 1992, 267:9474-9477.
10. Kino T., Hatanaka H., Miyata S., Inamura, Nishiyama M., Yajima T. FK506, a novel immunosuppressant isolated from a streptomyces. II. Immunosuppressive effect of FK506 in vitro. J Antibiot (Tokyo) 1987, 40:1256-1265.
11. Kokubun N., Sonoo M., Imai T., Arimura Y., Kuwabara S., Komori T., et al. Reference values for voluntary and stimulated single-fibre EMG using concentric needle electrodes: a multicentre prospective study. Clin Neurophysiol 2012, 123:613-620.
12. Konishi T., Yoshiyama Y., Takamori M., Saida T. Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus). J Neurol Neurosurg Psychiatry 2005, 76:448-450.
13. Kouyoumdjian J.A., Stålberg E. Reference jutter values for concentric needle electrodes in voluntarily activated extensor digitorum communis and orbicularis oculi muscles. Muscle Nerve 2008, 37:694-699.
14. Kuwabara S. Its's not the end: physiologic assessment of E-C coupling of muscle. Clin Neurophysiol 2010, 121:994-995.
15. Lanner J.T., Georgiou D.K., Joshi A.D., Hamilton S.L. Ryanodine receptors: structure, expression, molecular details, and function in calcium release. Cold Spring Harb Perspect Biol 2010, 2:a003996.
16. Leong P., MacLennan D.H. A 37-amino acid sequence in the skeletal muscle ryanodine receptor interacts with the cytoplasmic loop between domains II and III in the skeletal muscle dihydropyridine receptor. J Biol Chem 1998, 273:7791-7794.
17. Leong P., MacLennan D.H. The cytoplasmic loops between domains II and III and domains III and IV in the skeletal muscle dihydropyridine receptor bind to a contiguous site in the skeletal muscle ryanodine receptor. J Biol Chem 1998, 273:29958-29964.
18. Ma J., Bhat M.B., Zhao J. Rectification of skeletal muscle ryanodine receptor mediated by FK506 binding protein. Biophys J 1995, 69:2398-2404.
19. Maruta T., Yoshikawa H., Fukasawa S., Umeshita S., Inaoka Y., Edahiro S., et al. Autoantibody to dihydropyridine receptor in myasthenia gravis. J Neuroimmunol 2009, 208:125-129.
20. Minami N, Fujiki N, Doi S, Shima K, Niino M, Kikuchi S, et al. Five-year follow-up with low-dose tacrolimus in patients with myasthenia gravis. J Neurol Sci 2011;300:pp. 59-62.
21. Mygland Å., Tysnes O.B., Matre R., Volpe P., Aarli J.A., Gilhus N.E. Ryanodine receptor autoantibodies in myasthenia gravis patients with a thymoma. Ann Neurol 1992, 32:589-591.
22. Nagaishi A., Yukitake M., Kuroda Y. Long-term treatment of steroid-dependent Myasthenia gravis patients with low-dose tacrolimus. Intern Med 2008, 47:731-736.
23. Nagane Y., Utsugisawa K., Obara D., Kondoh R., Terayama Y. Efficacy of low-dose FK506 in the treatment of myasthenia gravis-a randomized pilot study. Eur Neurol 2005, 53:146-150.
24. Rousseff R.T., Khuraibet A.J., Al-Shubaili A.F., Tzvetanov P. Stimulated jitter in the masseter muscle: normative values. Muscle Nerve 2007, 35:243-245.
25. Rios E., Brum G. Involvement of dihydropyridine receptors in excitation-contraction coupling in skeletal muscle. Nature 1987, 325:717-720.
26. Sarrigiannis P.G., Kennett R.P., Simon R., Farrugia M.E. Single-fiber EMG with a concentric needle electrode: validation in myasthenia gravis. Muscle Nerve 2006, 33:61-65.
27. Schreiber S.L., Crabtree G.R. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992, 13:136-142.
28. Shiraishi H., Motomura M., Yoshimura T., Fukudome T., Fukuda T., Nakao Y., et al. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol 2005, 57:289-293.
29. Skeie G.O., Mygland Å., Treves S., Gilhus N.E., Aarli J.A., Zortato F. Ryanodine receptor antibodies in myasthenia gravis: epitope mapping and effect on calcium release in vitro. Muscle Nerve 2003, 27:81-89.
30. Takamori M., Motomura M., Kawaguchi N., Nemoto Y., Hattori T., Yoshikawa H., et al. Anti-ryanodine receptor antibodies and FK506 in myasthenia gravis. Neurology 2004, 62:1894-1896.
31. Tanabe T., Beam K.G., Adams B., Niidome T., Numa S. Regions of the skeletal muscle dihydropyridine receptor critical for excitation-contraction coupling. Nature 1990, 346:567-569.
32. Timerman A.P., Ogunbumni E., Freund E., Wiederrecht G., Marks A.R., Fleischer S. The calcium release channel of sarcoplasmic reticulum is modulated by FK-506-binding protein: dissociation and reconstitution of FKBP-12 to the calcium release channel of skeletal muscle sarcoplasmic reticulum. J Biol Chem 1993, 268:22992-22999.
33. Timerman A.P., Onoue H., Xin H.-B., Barg S., Copello J., Wiederrecht G., et al. Selective binding of FKBP12.6 by the cardiac ryanodine receptor. J Biol Chem 1996, 271:20385-20391.
34. Tsuda E., Imai T., Hozuki T., Yamauchi R., Saitoh M., Hisahara S., et al. Correlation of bite force with excitation-contraction coupling time of the masseter in myasthenia gravis. Clin Neurophysiol 2010, 121:1051-1058.
35. van der Bilt A., Weijnen F.G., Bosman F., van der Glas H.W., Kuks J.B.M. Controlled study of EMG activity of the jaw closers and openers during mastication in patients with myasthenia gravis. Eur J Oral Sci 2001, 109:160-164.
36. Weijnen F.G., van der Bilt A., Wokke J.J., Kuks J.B.M., van der Glas H.W., Bosman F. Maximal bite force and surface EMG in patients with myasthenia gravis. Muscle Nerve 2000, 23:1694-1699.